• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What Gastroenterologists Should Know About COVID-19 Vaccines.

作者信息

Rolak Stacey, Hayney Mary S, Farraye Francis A, Temte Jonathan L, Caldera Freddy

机构信息

Department of Medicine, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin.

School of Pharmacy, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin.

出版信息

Clin Gastroenterol Hepatol. 2021 Apr;19(4):657-661. doi: 10.1016/j.cgh.2021.01.001. Epub 2021 Feb 3.

DOI:10.1016/j.cgh.2021.01.001
PMID:33548200
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7857702/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ac/7857702/fbcfb8dd83dc/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ac/7857702/fbcfb8dd83dc/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ac/7857702/fbcfb8dd83dc/gr1_lrg.jpg

相似文献

1
What Gastroenterologists Should Know About COVID-19 Vaccines.胃肠病学家应了解的关于新冠疫苗的知识。
Clin Gastroenterol Hepatol. 2021 Apr;19(4):657-661. doi: 10.1016/j.cgh.2021.01.001. Epub 2021 Feb 3.
2
What Are COVID-19 Vaccines?什么是新冠疫苗？
Am J Respir Crit Care Med. 2021 May 1;203(9):P22-P23. doi: 10.1164/rccm.2021C2.
3
COVID-19 vaccination programme: a central role for primary care.2019冠状病毒病疫苗接种计划：初级保健的核心作用。
Br J Gen Pract. 2021 Jan 28;71(703):52-53. doi: 10.3399/bjgp21X714929. Print 2021.
4
Emerging COVID-19 vaccines: A rheumatology perspective.新兴的新冠疫苗：风湿病学视角
Int J Rheum Dis. 2021 Feb;24(2):144-146. doi: 10.1111/1756-185X.14048.
5
Number of Childhood and Adolescent Vaccinations Administered Before and After the COVID-19 Outbreak in Colorado.科罗拉多州 COVID-19 爆发前后儿童和青少年接种疫苗的数量。
JAMA Pediatr. 2021 Mar 1;175(3):305-307. doi: 10.1001/jamapediatrics.2020.4733.
6
SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?肾移植受者的新冠病毒2型疫苗：它们会安全有效吗？我们又如何得知？
J Am Soc Nephrol. 2021 May 3;32(5):1021-1024. doi: 10.1681/ASN.2021010023. Epub 2021 Mar 24.
7
COVID-19 may become nanomedicine's finest hour yet.新冠疫情或许会成为纳米医学迄今最辉煌的时刻。
Nat Nanotechnol. 2021 Apr;16(4):362-364. doi: 10.1038/s41565-021-00901-8.
8
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity.SARS-CoV-2 疫苗：从有效性数据和群体免疫障碍看问题
Respir Med. 2021 Apr-May;180:106355. doi: 10.1016/j.rmed.2021.106355. Epub 2021 Mar 6.
9
Protective Effect of COVID-19 Vaccine Among Health Care Workers During the Second Wave of the Pandemic in India.新冠疫情第二波期间印度医护人员接种新冠疫苗的保护作用
Mayo Clin Proc. 2021 Sep;96(9):2493-2494. doi: 10.1016/j.mayocp.2021.06.003. Epub 2021 Jun 26.
10
2021: The year in review.2021年回顾
J Allergy Clin Immunol. 2022 Mar;149(3):887-889. doi: 10.1016/j.jaci.2022.01.006. Epub 2022 Jan 22.

引用本文的文献

1
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.接受抗肿瘤坏死因子治疗的炎症性肠病患者接种3剂mRNA新冠疫苗后产生更高且持续的细胞介导免疫反应。
Clin Transl Gastroenterol. 2024 Apr 1;15(4):e00688. doi: 10.14309/ctg.0000000000000688.
2
COVID-19 Vaccination Among Individuals With Inflammatory Bowel Disease: Perception, Efficacy, and Safety.炎症性肠病患者的新冠病毒疫苗接种：认知、疗效与安全性
Gastroenterol Hepatol (N Y). 2022 Jul;18(7):388-399.
3
Effects of Different Biological Therapies on S1/S2 Antibody Response to SARS-CoV-2 Vaccination in a Cohort of Patients with Inflammatory Bowel Disease.

本文引用的文献

1
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.免疫实践咨询委员会关于使用辉瑞-BioNTech COVID-19 疫苗的临时建议-美国，2020 年 12 月。
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. doi: 10.15585/mmwr.mm6950e2.
2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
3
The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.
不同生物疗法对一组炎症性肠病患者接种SARS-CoV-2疫苗后S1/S2抗体反应的影响。
Vaccines (Basel). 2022 Jul 4;10(7):1077. doi: 10.3390/vaccines10071077.
4
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations.加拿大克罗恩病与结肠炎协会《2021年加拿大COVID-19与炎症性肠病的影响：COVID-19疫苗——生物学、现有证据及建议》
J Can Assoc Gastroenterol. 2021 Nov 5;4(Suppl 2):S54-S60. doi: 10.1093/jcag/gwab033. eCollection 2021 Dec.
5
SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients.肝硬化和肝移植患者第二次接种后针对 SARS-CoV2 的体液和 T 细胞免疫应答。
Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9. doi: 10.1016/j.cgh.2021.09.003. Epub 2021 Sep 9.
免疫实践咨询委员会分配 COVID-19 疫苗初始供应的道德原则-美国，2020 年。
MMWR Morb Mortal Wkly Rep. 2020 Nov 27;69(47):1782-1786. doi: 10.15585/mmwr.mm6947e3.
4
Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination.与美国成年人接受 COVID-19 疫苗意愿相关的因素。
JAMA Netw Open. 2020 Oct 1;3(10):e2025594. doi: 10.1001/jamanetworkopen.2020.25594.
5
Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.新冠疫苗的紧急使用授权——安全性和有效性随访考量
N Engl J Med. 2020 Nov 5;383(19):e107. doi: 10.1056/NEJMp2031373. Epub 2020 Oct 16.
6
Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.美国新冠疫苗批准后安全性监测
JAMA. 2020 Nov 17;324(19):1937-1938. doi: 10.1001/jama.2020.19692.
7
SARS-CoV-2 vaccines in development.正在研发中的 SARS-CoV-2 疫苗。
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
8
Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach.开发安全有效的新冠疫苗——“极速行动”计划的策略与方法。
N Engl J Med. 2020 Oct 29;383(18):1701-1703. doi: 10.1056/NEJMp2027405. Epub 2020 Aug 26.
9
Unwavering Regulatory Safeguards for COVID-19 Vaccines.对新冠疫苗坚定不移的监管保障措施。
JAMA. 2020 Sep 8;324(10):931-932. doi: 10.1001/jama.2020.15725.
10
Developing Covid-19 Vaccines at Pandemic Speed.以大流行速度研发新冠疫苗。
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.